Ligand modulated antagonism of PPARγ by genomic and non-genomic actions of PPARδ

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Gustafsson, Mattias C U ^a,b   Knight, Deborah ^a,c   Palmer, Colin N A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FACTOR AF2; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; LIGAND;

ANIMAL CELL; ARTICLE; DIMERIZATION; DNA BINDING; GENE DELETION; GENE INTERACTION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSFECTION; LIGAND BINDING; NONHUMAN; PROTEIN DOMAIN; REPORTER GENE; SIGNAL TRANSDUCTION; ANIMAL; CELL NUCLEUS; CELL STRAIN COS1; CERCOPITHECUS; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; ESCHERICHIA COLI; GENOME; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; CERCOPITHECUS AETHIOPS; COS CELLS; DIMERIZATION; ESCHERICHIA COLI; GENOME; HUMANS; LIGANDS; PPAR DELTA; PPAR GAMMA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION;

EID: 70349492462     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007046     Document Type: Article

References (36)

1. Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688.
2. Staels B, Fruchart JC (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54: 2460-2470.
3. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550.
4. Tachibana K, Yamasaki D, Ishimoto K, Doi T (2008) The Role of PPARs in Cancer. PPAR Res 2008: 102737.
5. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem 77: 289-312.
6. Abbott BD (2008) Review of the expression of peroxisome proliferators-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development. Reprod Toxicol.
7. Desvergne B, Michalik L, Wahli W (2006) Transcriptional regulation of metabolism. Physiol Rev 86: 465-514.
8. Seedorf U, Aberle J (2007) Emerging roles of PPARδ in metabolism. Biochim Biophys Acta 1771: 1125-1131.
9. Takahashi S, Tanaka T, Sakai J (2007) New therapeutic target for metabolic syndrome: PPARδ. Endocr J 54: 347-357.
10. Riserus U, Sprecher D, Johnson T, Olson E, Hirschberg S, et al. (2008) Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57: 332-339.
11. Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, et al. (2007) Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arterioscler Thromb Vasc Biol 27: 359-365.
12. Krogsdam AM, Nielsen CA, Neve S, Holst D, Helledie T, et al. (2002) Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor δ-mediated transactivation. Biochem J 363: 157-165.
13. Shi Y, Hon M, Evans RM (2002) The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A 99: 2613-2618.
14. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, et al. (1999) Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883.
15. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T (2001) Prostacyclin-dependent apoptosis mediated by PPARd. J Biol Chem 276: 46260-46267.
16. Michalik L, Feige JN, Gelman L, Pedrazzini T, Keller H, et al. (2005) Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing. Mol Endocrinol 19: 2335-2348.
17. Targett-Adams P, McElwee MJ, Ehrenborg E, Gustafsson MC, Palmer CN, et al. (2005) A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. Biochim Biophys Acta 1728: 95-104.
18. Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci U S A 94: 4312-4317.
19. He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARd is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
20. Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, et al. (2008) Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NR1C2) antagonist. Mol Endocrinol 22: 523-529.
21. Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, et al. (2003) Cross-talk between peroxisome proliferator-activated receptor (PPAR) α and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endocrinol 17: 1255-1267.
22. Yoshikawa T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, et al. (2003) Cross-talk between peroxisome proliferator-activated receptor (PPAR) α and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol Endocrinol 17: 1240-1254.
23. Matsusue K, Miyoshi A, Yamano S, Gonzalez FJ (2006) Ligand-activated PPARβ efficiently represses the induction of LXR-dependent promoter activity through competition with RXR. Mol Cell Endocrinol 256: 23-33.
24. Chu R, Madison LD, Lin Y, Kopp P, Rao MS, et al. (1995) Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of genes encoding β-oxidation enzymes: cross talk between peroxisome proliferator and T3 signaling pathways. Proc Natl Acad Sci U S A 92: 11593-11597.
25. Ying H, Araki O, Furuya F, Kato Y, Cheng SY (2007) Impaired adipogenesis caused by a mutated thyroid hormone a1 receptor. Mol Cell Biol 27: 2359-2371.
26. Araki O, Ying H, Furuya F, Zhu X, Cheng SY (2005) Thyroid hormone receptor β mutants: Dominant negative regulators of peroxisome proliferator-activated receptor γ action. Proc Natl Acad Sci U S A 102: 16251-16256.
27. Sambrook J, Russell DW (2001) Molecular Cloning: A laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
28. Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN (2002) Diclofenac antagonizes peroxisome proliferator-activated receptor-c signaling. Mol Pharmacol 61: 7-12.
29. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, et al. (1992) Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6: 1634-1641.
30. Solomin L, Johansson CB, Zetterstrom RH, Bissonnette RP, Heyman RA, et al. (1998) Retinoid-X receptor signalling in the developing spinal cord. Nature 395: 398-402.
31. Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, et al. (1993) Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A 90: 30-34.
32. Kalkhoven E, Valentine JE, Heery DM, Parker MG (1998) Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. Embo J 17: 232-243.
33. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, et al. (2001) The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J Biol Chem 276: 44258-44265.
34. Aiyar N, Baker E, Wu HL, Nambi P, Edwards RM, et al. (1994) Human AT1 receptor is a single copy gene: characterization in a stable cell line. Mol Cell Biochem 131: 75-86.
35. Cullen BR (1987) Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol 152: 684-704.
36. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956.